Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1101 daily bars · split adjusted
Current price $0.1505
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-03-16
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 19.31 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 17.56 | Oscillator | Buy |
| Williams %R (14) | -70.45 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.18 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 40.46 (+DI 9.7 / -DI 39.2) | Trend | Strong Sell |
| EMA 20 | 0.34 | MA | Strong Sell |
| SMA 20 | 0.37 | MA | Strong Sell |
| EMA 50 | 0.62 | MA | Strong Sell |
| SMA 50 | 0.72 | MA | Strong Sell |
| SMA 200 | 1.34 | MA | Strong Sell |
FY2019 · 10-K disclosure
Stock news · updated daily
CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings. Profitability This table compares CASI Pharmaceuticals and
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026. "We remained focused on advancing the development of our lead program, CID-103," said Dr. Wei-Wu He, Executive Chairman and Principal Executive Officer of CASI.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Nov 14, 2025 | -0.40 | -0.67 | Miss -67.5% | $3.08M |
| Aug 29, 2025 | -0.47 | -0.86 | Miss -83.0% | $4.17M |
| May 16, 2025 | -0.61 | -0.69 | Miss -13.1% | $6.24M |
| Mar 31, 2025 | -0.60 | -0.79 | Miss -31.7% | $13.36M |
| Nov 15, 2024 | -0.62 | -0.55 | Beat 11.3% | $7.79M |
| Aug 16, 2024 | -0.63 | -0.52 | Beat 17.5% | $3.98M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Mar 18, 26 | Huang James | director | 0 | — | |
| Mar 18, 26 |
| Huang James |
| director |
| 10,000 @ $1.69 |
| $16.90K |
| Mar 18, 26 | Huang James | director | 10,000 @ $2.69 | $26.90K |
| Mar 18, 26 | Huang James | director | 101,571 @ $1.93 | $196.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CASI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | -3.0x · sector 20.7x | Discount |
| Forward P/E (FY25E) | -0.1x | EPS est. -2.58 | Discount |
| Price / Book | -0.1x | 6.6x | Discount |
| Price / Sales | 0.4x | 6.0x | Discount |
| EV / EBITDA | -0.8x | -3.3x | Discount |
| Return on equity | 99.2% | — | Top tier |
| Gross margin | 38.1% | 51.4% | Below hist. |
| Debt / Equity | -0.66 | 2.59 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -47.98 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Sep 2, 2026 | 2026-09-02 07:00:19 | View |
| 6-K | Aug 14, 2026 | 2026-08-14 07:00:10 | View |
| 6-K | Aug 13, 2026 | 2026-08-13 16:30:14 | View |
| 6-K | Jul 15, 2026 | 2026-07-15 06:30:32 | View |
| 6-K | Jun 29, 2026 | 2026-06-29 06:30:21 | View |
| 25-NSE | Jun 23, 2026 | 2026-06-23 13:45:22 | View |
| 6-K | Jun 2, 2026 | 2026-06-02 06:30:39 | View |
| SC 13D/A | May 18, 2026 | 2026-05-18 16:30:15 | View |
| 20-F | May 15, 2026 | 2026-05-15 06:16:07 | View |
| D | Apr 28, 2026 | 2026-04-28 06:05:10 | View |
Proxy statement (DEF 14A) disclosures